IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 26-50 out of 1364.

<< < 1 | 2 | 3 | 4 | 5 | 6 > >>

Public Release: 30-Jun-2015
Bulletin of the World Health Organization
Epidemic of obesity and overweight linked to increased food energy supply
This study investigates the associations between changes in national food energy supply and average population body weight in 24 high-, 27 middle- and 18 low-income countries. The authors found that the association between change in energy supply and change in weight was statistically significant overall, with findings suggesting that increases in food energy supply are sufficient to explain increases in average population weight.
University of Auckland Vice Chancellor's Strategic Fund, National Institutes of Health

Contact: Fiona Fleck
fleckf@who.int
41-227-911-897
Bulletin of the World Health Organization

Public Release: 29-Jun-2015
Circulation
Sugary drinks linked to high death tolls worldwide
Consumption of sugary drinks may lead to an estimated 184,000 adult deaths each year worldwide, according to research published today in the journal Circulation and previously presented as an abstract at the American Heart Association Council on Epidemiology and Prevention in 2013.
NIH/National Institute of Diabetes and Digestive and Kidney Diseases, NIH/National Heart, Lung and Blood Institute, Bill & Melinda Gates Foundation

Contact: Andrea Grossman
617-636-3728
Tufts University, Health Sciences Campus

Public Release: 29-Jun-2015
Nature Genetics
Pinpointing mutations in a relapsed children's cancer may lead to improved treatments
Researchers studying the pediatric cancer neuroblastoma have detailed how cancer-driving mutations evolve during chemotherapy, and they hope to exploit this knowledge to design better treatments for children.
National Institutes of Health, University of Pennsylvania Genome Frontiers Institute

Contact: Ashley Moore
MooreA1@email.chop.edu
267-426-6071
Children's Hospital of Philadelphia

Public Release: 29-Jun-2015
Proceedings of the National Academy of Sciences
Treatment with PI3K inhibitors may cause cancers to become more aggressive and metastatic
The enzyme PI3K appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target. However, PI3K inhibitors have only shown modest clinical activity. Now, new research from The Wistar Institute shows that treatment with PI3K inhibitors alone may actually make a patient's cancer even worse by promoting more aggressive tumor cell behavior and increasing the cancer's potential of spreading to other organs.
National Institutes of Health, Prostate Cancer Research Program, Joint Grant in Molecular Medicine from Fondazione IRCCS Ca' Granda, Instituto Nazionale Genetica Molecolare

Contact: Ben Leach
bleach@wistar.org
215-495-6800
The Wistar Institute

Public Release: 29-Jun-2015
Proceedings of the National Academy of Sciences
New family of small RNAs boosts cell proliferation in cancer
Rather than cellular trash, half of a transfer RNA (tRNA) molecule appears to actively spur cell proliferation in breast and prostate cancers, suggesting a new role for tRNA and a possible target for a new class of therapy.

Contact: Edyta Zielinska
edyta.zielinska@jefferson.edu
215-955-5291
Thomas Jefferson University

Public Release: 29-Jun-2015
Journal of Clinical Oncology
Researchers define unique group of high-risk lymphoma patients
About 20 percent of follicular lymphoma patients consistently experience their disease coming back within two years of being treated with the latest therapies. New research confirms that patients in this group have very poor survival outcomes; 50 percent die in five years. People who relapse early may have a disease with distinctly different biology and should not be approached the same at diagnosis nor at the time of relapse in terms of therapies.
Genentech, F. Hoffmann-La Roche

Contact: Leslie Orr
leslie_orr@urmc.rochester.edu
585-275-3676
University of Rochester Medical Center

Public Release: 29-Jun-2015
Molecular Oncology
Mayo Clinic study suggests which glioblastoma patients may benefit from drug treatment
Clinicians testing the drug dasatinib, approved for several blood cancers, had hoped it would slow the aggressive growth of the deadly brain cancer glioblastoma; however, clinical trials to date have not found any benefit. Researchers at Mayo Clinic, who conducted one of those clinical trials, believe they know why dasatinib failed -- and what to do about it.
National Institutes of Health

Contact: Kevin Punsky
punsky.kevin@mayo.edu
904-953-0746
Mayo Clinic

Public Release: 29-Jun-2015
Nature Communications
Danish researchers map important enzyme in the fight against cancer
Researchers from the University of Copenhagen have discovered what regulates an enzyme that is central to the growth of cancer tumors. This could be of great value to future cancer treatment.

Contact: Sarah Dombernowsky
sarah.dombernowsky@bric.ku.dk
45-22-88-21-86
University of Copenhagen The Faculty of Health and Medical Sciences

Public Release: 26-Jun-2015
Genes & Development
Braking mechanism identified for cell growth pathway linked to several cancers
Researchers at University of California, San Diego School of Medicine have discovered a self-regulating loop in the Hippo pathway, a signaling channel garnering increased attention from cancer researchers due to its role in controlling organ size, cell proliferation and cell death.
National Institutes of Health, Japan Society for the Promotion of Science, Yasuda Medical Foundation, UC San Diego

Contact: Bonnie Ward
bjward@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 26-Jun-2015
Journal of Investigative Dermatology
Action spectrum of sun skin damage documented
Scientists at Newcastle University have documented for the first time the DNA damage which can occur to skin across the full range of ultraviolet radiation from the sun providing an invaluable tool for sun-protection and the manufacturers of sunscreen.
Engineering and Physical Sciences Research Council, Proctor and Gamble

Contact: Karen Bidewell
karen.bidewell@ncl.ac.uk
44-019-120-86972
Newcastle University

Public Release: 26-Jun-2015
Cancer Cell
SLU scientists develop potential new class of cancer drugs in lab
The new drug targets the Warburg effect to cut off cancer's energy supply.

Contact: Carrie Bebermeyer
bebermcl@slu.edu
314-977-8015
Saint Louis University

Public Release: 25-Jun-2015
Scientific Reports
New class of compounds shrinks pancreatic cancer tumours and prevents regrowth
Scientists from UCL (University College London) have designed a chemical compound that has reduced the growth of pancreatic cancer tumours by 80 percent in treated mice. The compound, called MM41, was designed to block faulty genes. It appears to do this by targeting little knots in their DNA, called quadruplexes, which are very different from normal DNA and which are especially found in faulty genes.
Pancreatic Cancer Research Fund

Contact: Abi Chard
abigail@campuspr.co.uk
07-960-448-532
University College London

Public Release: 25-Jun-2015
Science Translational Medicine
Experimental treatment sends deadly leukemia into remission
An experimental new treatment approach for a rare, deadly leukemia can send the disease into remission even in patients for whom the standard therapy has failed, a pilot study has found. The study is 'proof of principle' the cutting-edge approach could be used to treat many other cancers as well.

Contact: Josh Barney
jdb9a@virginia.edu
434-906-8864
University of Virginia Health System

Public Release: 25-Jun-2015
Journal of the National Cancer Institute
Development of new blood vessels not essential to growth of lymph node metastases
A Massachusetts General Hospital Cancer Center research team reports has found that the growth of metastases in lymph nodes -- the most common site of cancer spread -- does not require the development of new blood vessels, potentially explaining why antiangiogenesis drugs have failed to prevent the development of new metastases.
National Institutes of Health, National Cancer Institute

Contact: Katie Marquedant
kmarquedant@partners.org
617-726-0337
Massachusetts General Hospital

Public Release: 25-Jun-2015
Cell Metabolism
New drug squashes cancer's last-ditch efforts to survive
The Salk Institute and Sanford Burnham Prebys Medical Discovery Institute created a compound that stops a cellular recycling process.

Contact: Salk Communications
press@salk.edu
858-453-4100
Salk Institute

Public Release: 25-Jun-2015
Chemistry & Biology
New approach holds promise for earlier, easier detection of colorectal cancer
Chemists at Caltech have developed a new sensitive electrochemical technique capable of detecting colorectal cancer in tissue samples -- a method that could one day be used in clinical settings for the early diagnosis of colorectal cancer.
National Institutes of Health

Contact: Deborah Williams-Hedges
debwms@caltech.edu
626-395-3227
California Institute of Technology

Public Release: 25-Jun-2015
Scientific Reports
IU research: A microRNA may provide therapy against pancreatic cancer
Indiana University cancer researchers found that a particular microRNA may be a potent therapeutic agent against pancreatic cancer. The research was published June 22 in the journal Scientific Reports.
Elsa U. Pardee Foundation

Contact: Michael Schug
maschug@iupui.edu
317-278-0953
Indiana University

Public Release: 25-Jun-2015
Oncotarget
Compound in magnolia may combat head and neck cancers
As one of the compounds in magnolia extract, honokiol has been used for centuries in traditional Chinese and Japanese medicine to treat anxiety and other conditions. More recently, scientists, including a team with the Department of Veterans Affairs and the University of Alabama at Birmingham, have been revealing its cancer-fighting properties.
US Department of Veterans Affairs

Contact: Jeffrey Hester
Jeffrey.Hester@va.gov
205-558-4744
Veterans Affairs Research Communications

Public Release: 25-Jun-2015
Nucleic Acids Research
Cancer and vampires: An evolutionary approach
A Hebrew University of Jerusalem scientist has developed a new Internet tool that will allow any investigator, physician or patient to analyze genes according to their evolutionary profile and find associated genes. The tool combines genomics and informatics to enables the rapid, cost-free identification of genes responsible for diseases, by inputting results from genetic mapping studies concerning suspected genes, and identifying connections to known genes with association to diseases.
Hebrew University of Jerusalem

Contact: Dov Smith
dovs@savion.huji.ac.il
972-258-82844
The Hebrew University of Jerusalem

Public Release: 24-Jun-2015
Nature
Targeting telomeres, the timekeepers of cells, could improve chemotherapy
In an unexpected finding, the Salk Institute and collaborators show how disabling telomere protection during cell division prompts cell death.

Contact: Salk Communications
press@salk.edu
Salk Institute

Public Release: 24-Jun-2015
Nature Communications
Eavesdropping on the body: New device tracks chemical signals within cells
Biomedical engineers at the University of Toronto have invented a new device that more quickly and accurately 'listens in' on the chemical messages that tell our cells how to multiply. The tool improves our understanding of how cancerous growth begins, and could identify new targets for cancer medications.

Contact: RJ Taylor
rj.taylor@utoronto.ca
416-978-4498
University of Toronto Faculty of Applied Science & Engineering

Public Release: 24-Jun-2015
Science Translational Medicine
DNA shed from head and neck tumors detected in blood and saliva
On the hunt for better cancer screening tests, Johns Hopkins scientists led a proof of principle study that successfully identified tumor DNA shed into the blood and saliva of 93 patients with head and neck cancer. A report on the findings is published in the June 24 issue of Science Translational Medicine.
Virginia and D.K. Ludwig Fund for Cancer Research, Conrad R. Hilton Foundation, Banyan Gate Foundation, Swim Across America, Sol Goldman Sequencing Facility at Johns Hopkins, NIH/National Cancer Institute

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine

Public Release: 24-Jun-2015
New England Journal of Medicine
Detroit patients' contributions to national study re-define low-grade brain tumor diagnosis
Sixty-seven patients from the Hermelin Brain Tumor Center at Henry Ford Hospital and their families made important contributions to a national cancer study that proposes a change in how some brain tumors are classified and ultimately treated. Published in the July 25 issue of the New England Journal of Medicine, the study reveals that a tumor's DNA is key to determining if a lower-grade malignant brain tumor may rapidly progress to glioblastoma.

Contact: Krista Hopson Boyer
kboyer1@hfhs.org
313-874-7207
Henry Ford Health System

Public Release: 24-Jun-2015
Eating Behaviors
Eating in the absence of hunger: A recipe for expanding waistline
QUT researcher Dr Stephanie Fay has found that snacking when you're not hungry can cause weight gain as much as overly large portion sizes and energy-rich foods. Her findings have just been published in an international journal.

Contact: Amanda Weaver
amanda.weaver@qut.edu.au
Queensland University of Technology

Public Release: 24-Jun-2015
Nature
Tiny particles in blood useful for early diagnosis of pancreatic cancer
A protein encoded by the gene glypican-1 present on cancer exosomes may be used as part of a potential non-invasive diagnostic and screening tool to detect early pancreatic cancer, potentially at a stage amenable to surgical treatment, according to a study at The University of Texas MD Anderson Cancer Center.

Contact: Ron Gilmore
rlgilmore1@mdanderson.org
713-745-1898
University of Texas M. D. Anderson Cancer Center

Showing releases 26-50 out of 1364.

<< < 1 | 2 | 3 | 4 | 5 | 6 > >>

  Search News Releases

     

 

EurekAlert!